Tech Company Financing Transactions
EnClear Therapies Funding Round
Bioverge, Presight Capital and Sanford Biosciences participated in a $2 million Seed venture round for EnClear Therapies. The round was recorded on 3/15/2019.
Transaction Overview
Company Name
Announced On
3/15/2019
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Seed
Proceeds Purpose
The company intends to use the funds to advance development of its therapies.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
65 Parker St. 3A.
Newburyport, MA 01950
USA
Newburyport, MA 01950
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
EnClear Therapies was conceived by the founders of QurAlis and Q-State Bio, with the sole purpose of developing novel device-based therapies to treat patients with neurodegenerative disease. The companies first products will aim to halt the progression of ALS and PSP.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jonathan Fleming
Chief Executive Officer
Anthony DePasqua
Chief Medical Officer
William Gormley
Chief Scientific Officer
Kasper Roet
Co-Founder
Kevin Eggan
VP - R & D
Kevin Kalish
VP - R & D
William Siopes
Browse more venture capital transactions:
Prev: 3/14/2019: CesiumAstro venture capital transaction
Next: 3/15/2019: Polarr venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs